Loading patent…
AssigneeMemorial Sloan Kettering Cancer Center
InventorsLiang Deng, Stewart Shuman, Ning Yang, Weiyi Wang, Peihong Dai
Estimating the term…
Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVAΔC7L and VACVΔC7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVAΔC7L or VACVΔC7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).
An engineered modified vaccinia Ankara (MVA) virus strain comprising a disruption of a C7L gene.
(canceled)
-6. (canceled)
(canceled)
(canceled)
An engineered attenuated vaccinia virus (VACV) strain comprising a disruption of a C7L gene.
-22. (canceled)
A recombinant vaccinia virus (VACV) nucleic acid sequence,
-35. (canceled)
A method for treating a solid tumor in a subject in need thereof, the method comprising delivering to a tumor a composition comprising an effective amount of an engineered modified vaccinia Ankara (MVA) virus strain comprising a disruption of a C7L gene (MVAΔC7L), a MVAΔC7L virus genetically engineered to express hFlt3L (MVAΔC7L-hFlt3L), or combinations thereof;
-51. (canceled)
Dependencies are inferred from the claim text.